Download PDF
Thromb Haemost 1995; 73(05): 812-818
DOI: 10.1055/s-0038-1653873
Original Articles
Coagulation
Schattauer GmbH Stuttgart

Transforming Growth Factor Betal and Beta2 Induce Down-Modulation of Thrombomodulin in Human Umbilical Vein Endothelial Cells

Taro Ohji
1   Department of Pediatrics, University of Occupational and Environmental Health, School of Medicine, Kitakyushu City, Japan
,
Hajime Urano
1   Department of Pediatrics, University of Occupational and Environmental Health, School of Medicine, Kitakyushu City, Japan
,
Akira Shirahata
1   Department of Pediatrics, University of Occupational and Environmental Health, School of Medicine, Kitakyushu City, Japan
,
Minoru Yamagishi
1   Department of Pediatrics, University of Occupational and Environmental Health, School of Medicine, Kitakyushu City, Japan
,
Ken Higashi
2   Department of Biochemistry, University of Occupational and Environmental Health, School of Medicine, Kitakyushu City, Japan
,
Sadao Gotoh
2   Department of Biochemistry, University of Occupational and Environmental Health, School of Medicine, Kitakyushu City, Japan
,
Yuji Karasaki
2   Department of Biochemistry, University of Occupational and Environmental Health, School of Medicine, Kitakyushu City, Japan
› Author Affiliations
Further Information

Publication History

Received 11 October 1994

Accepted after revision 06 February 1995

Publication Date:
09 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

To investigate the effects of transforming growth factor-betas (TGF-βs) on endothelial anticoagulant activity, we assayed thrombomodulin (TM) activity and antigen levels of human umbilical vein endothelial cells (HUVECs) incubated with TGF-βs in vitro. TGF-β1 suppressed surface TM activity and surface TM antigen levels maximally 12 h after incubation in dose-dependent manners. TGF-β2 was almost equipotent with TGF-β1 for the suppression of them. Both TGF-βs suppressed total TM antigen level in HUVECs, and the time course of the suppression was similar to that of the cell surface TM antigen level. The maximal reductions of TM mRNA levels by TGF-βs were observed at several hours ahead of those observed in both surface and total TM antigen levels, suggesting that the TGF-β-mediated suppression of TM antigen of HUVECs is primarily regulated at the TM mRNA level. Our present work suggests that the down-modulation of TM level induced by TGF-βs in HUVECs contributes in vivo to promoting the thrombogenesis either at the sites of injury of vessel walls, such as atherosclerotic lesions where TGF-β1 is released from platelets, smooth muscle cells and monocytes, or at neovascular walls in tumors secreting TGF-β2.

 

  • References

  • 1 Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB. Transforming growth factor-β in human platelets: identification of a major storage site, purification, and characterization. J Biol Chem 1983; 258: 7155-7160
    PubMedGoogle Scholar
  • 2 Bithell TC. Normal Hemostasis and Coagulation. In: Leavell and Thorup’s Fundamentals of Clinical Hematology. Thorup Jr OA. ed W. B. Saunders Company; Philadelphia, PA: 1987. pp 126-162
    Google Scholar
  • 3 Assoian RK, Sporn MB. Type β transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. J Cell Biol 1986; 102: 1217-1223
    CrossrefPubMedGoogle Scholar
  • 4 Majesky MW, Lindner V, Twardzik DR, Schwartz SM, Reidy MA. Production of transforming growth factor β1 during repair of arterial injury. J Clin Invest 1991; 88: 904-910
    CrossrefPubMedGoogle Scholar
  • 5 Taipale J, Koli K, Keski-Oja J. Release of transforming growth factor-β1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin. J Biol Chem 1992; 267: 25378-25384
    PubMedGoogle Scholar
  • 6 Roberts AB, Flanders KC, Kondaiah P, Thompson NL, Van Obberghen-SchillingE, Wakefield L, Rossi P, De CrombruggheB, Heine U, Sporn MB. Transforming growth factor β: biochemistry and roles in embryogenesis, tissue repair and remodeling, and carcinogenesis. Recent Prog Horm Res 1988; 44: 157-197
    PubMedGoogle Scholar
  • 7 Massagué J. The transforming growth factor-β family. Annu Rev Cell Biol 1990; 6: 597-641
    CrossrefPubMedGoogle Scholar
  • 8 Saksela O, Moscatelli D, Rifkin DB. The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells. J Cell Biol 1987; 105: 957-963
    CrossrefPubMedGoogle Scholar
  • 9 de MartinR, Haendler B, Hofer-Warbinek R, Gaugitsch H, Wrann M, Schlusener H, Seifert JM, Bodmer S, Fontana A, Hofer E. Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-β gene family. EMBO J 1987; 6: 3673-3677
    PubMedGoogle Scholar
  • 10 Wrann M, Bodmer S, de Martin R, Siepl C, Hofer-Warbinek R, Frei K, Hofer E, Fontana A. T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-β. EMBO J 1987; 6: 1633-1636
    PubMedGoogle Scholar
  • 11 Ikeda T, Lioubin MN, Marquardt H. Human transforming growth factor type β2 production by a prostatic adenocarcinoma cell line, purification, and initial characterization. Biochemistry 1987; 26: 2406-2410
    CrossrefPubMedGoogle Scholar
  • 12 Hirai R, Kaji K. Transforming growth factor β1-specific binding proteins on human vascular endothelial cells. Exp Cell Res 1992; 201: 119-125
    CrossrefPubMedGoogle Scholar
  • 13 Cheifetz S, Hernandez H, Laiho M, ten DijkeP, Iwata KK, Massagué J. Distinct transforming growth factor-β (TGF-β) receptor subsets as determinants of cellular responsiveness to three TGF-β isoforms. J Biol Chem 1990; 265: 20533-20538
    PubMedGoogle Scholar
  • 14 Cheifetz S, Bellón T, Calés C, Vera S, Bernabeu C, Massagué J, Letarte M. Endoglin is a component of the transforming growth factor-P receptor system in human endothelial cells. J Biol Chem 1992; 267: 19027-19030
    PubMedGoogle Scholar
  • 15 Jennings JC, Mohan S, Linkhart TA, Widstrom R, Baylink DJ. Comparison of the biological actions of TGF beta-1 and TGF beta-2 differential activity in endothelial cells. J Cell Physiol 1988; 137: 167-172
    CrossrefPubMedGoogle Scholar
  • 16 Merwin JR, Newman W, Beall LD, Tucker A, Madri J. Vascular cells respond differentially to transforming growth factors betal and beta2 in vitro. Am J Pathol 1991; 138: 37-51
    PubMedGoogle Scholar
  • 17 Ohta M, Greenberger JS, Anklesaria P, Bassols A, Massagué J. Two forms of transforming growth factor-β distinguished by multipotential haematopoietic progenitor cells. Nature 1987; 329: 539-541
    CrossrefPubMedGoogle Scholar
  • 18 Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743-4746
    PubMedGoogle Scholar
  • 19 Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79: 124-130
    CrossrefPubMedGoogle Scholar
  • 20 Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989; 73: 159-165
    PubMedGoogle Scholar
  • 21 Nawroth PP, Handley DA, Esmon CT, Stem DM. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci USA 1986; 83: 3460-3464
    CrossrefPubMedGoogle Scholar
  • 22 Horie S, Kizaki K, Ishii H, Kazama M. Retinoic acid stimulates expression of thrombomodulin, a cell surface anticoagulant glycoprotein, on human endothelial cells. Biochem J 1992; 281: 149-154
    CrossrefPubMedGoogle Scholar
  • 23 Hirokawa K, Aoki N. Up-regulation of thrombomodulin by activation of histamine HI-receptors in human umbilical-vein endothelial cells in vitro. Biochem J 1991; 276: 739-743
    CrossrefPubMedGoogle Scholar
  • 24 Hirokawa K, Aoki N. Regulatory mechanisms for thrombomodulin expression in human umbilical vein endothelial cells in vitro. J Cell Physiol 1991; 147: 157-165
    CrossrefPubMedGoogle Scholar
  • 25 Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria J Clin Invest 1973; 52: 2745-2756
    PubMedGoogle Scholar
  • 26 Netland PA, Zetter BR, Via DP, Voyta JC. In situ labelling of vascular endothelium with fluorescent acetylated low density lipoprotein. Histo-chem J 1985; 17: 1309-1320
    CrossrefPubMedGoogle Scholar
  • 27 Kodama S, Uchijima E, Nagai M, Mikawatani K, Hayashi T, Suzuki K. One-step sandwich enzyme immunoassay for soluble human thrombomodulin using monoclonal antibodies. Clin Chim Acta 1990; 192: 191-200
    CrossrefPubMedGoogle Scholar
  • 28 Suzuki K, Kusumoto H, Deyashiki Y, Nishioka J, Maruyama I, Zushi M, Kawahara S, Honda G, Yamamoto S, Horiguchi S. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor protein C activation. EMBO J 1987; 6: 1891-1897
    CrossrefPubMedGoogle Scholar
  • 29 Fràter-Schröder M, Millier G, Birchmeier W, Böhlen P. Transforming growth factor-beta inhibits endothelial cell proliferation. Biochem Biophys Res Commun 1986; 137: 295-302
    CrossrefPubMedGoogle Scholar
  • 30 Cheifetz S, Weatherbee JA, Tsang ML S, Anderson JK, Mole JE, Lucas R, Massagué J. The transforming growth factor-β system, a complex pattern of cross-reactive ligands and receptors. Cell 1987; 48: 409-415
    CrossrefPubMedGoogle Scholar
  • 31 Ottmann OG, Pelus LM. Differential proliferative effects of transforming growth factor-β on human hematopoietic progenitor cells. J Immunol 1988; 140: 2661-2665
    PubMedGoogle Scholar
  • 32 Danielpour D, Spom MB. Differential inhibition of transforming growth factor β1 and β2 activity by α2-macroglobulin. J Biol Chem 1990; 265: 6973-6977
    PubMedGoogle Scholar
  • 33 Wrana JL, Attisano L, Cárcamo J, Zentella A, Doody J, Laiho M, Wang XF, Massagué J. TGFβ signals through a heteromeric protein kinase receptor complex. Cell 1992; 71: 1003-1014
    CrossrefPubMedGoogle Scholar
  • 34 López-Casillas F, Wrana JL, Massagué J. Betaglycan presents ligand to the TGFβ signaling receptor. Cell 1993; 73: 1435-1444
    CrossrefPubMedGoogle Scholar
  • 35 O’Grady P, Kuo MD, Baldassare JJ, Huang SS, Huang JS. Purification of a new type high molecular weight receptor (type V receptor) of transforming growth factor β (TGF-β) from bovine liver: identification of the type V TGF-β receptor in cultured cells. J Biol Chem 1991; 266: 8583-8589
    PubMedGoogle Scholar
  • 36 O’Grady P, Huang SS, Huang JS. Expression of a new type high molecular weight receptor (type V receptor) of transforming growth factor β in normal and transformed cells. Biochem Biophys Res Commun 1991; 179: 378-385
    CrossrefPubMedGoogle Scholar
  • 37 Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone Jr MA. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984; 160: 618-623
    CrossrefPubMedGoogle Scholar
  • 38 Ross R. The pathogenesis of atherosclerosis - an update. N Engl J Med 1986; 314: 488-500
    CrossrefPubMedGoogle Scholar
  • 39 Sato Y, Rifkin DB. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-βl- like molecule by plasmin during co-culture. J Cell Biol 1989; 109: 309-315
    CrossrefPubMedGoogle Scholar